20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Incidence of GBS and CIDP Following Influenza Vaccination
25:18 MIN
- CIDP
- GBS
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
15:18 MIN
- CIDP
- GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5:24 MIN
- CIDP
Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
25:18
Incidence of GBS and CIDP Following Influenza Vaccination
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
NOW PLAYING
5:24
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.
Our Experts on CIDP
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
- CIDP
- MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
- CIDP
- GBS
- MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
- CIDP
- GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Slides & Posters about CIDP
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
PDF | 1.4 MB
CIDP Assessment Tools: Grip Strength
PDF |
IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
PDF | 250 KB
Back to Top